Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.59M | 55.63M | 55.23M | 62.60M | 74.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.59M | 55.63M | 55.23M | 62.60M | 74.93M |
| Cost of Revenue | -- | -- | -- | 7.98M | 12.41M |
| Gross Profit | 54.59M | 55.63M | 55.23M | 54.62M | 62.52M |
| SG&A Expenses | 53.46M | 57.77M | 68.67M | 74.62M | 77.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.23M | 180.30M | 186.00M | 198.96M | 214.06M |
| Operating Income | -130.64M | -124.66M | -130.77M | -136.36M | -139.13M |
| Income Before Tax | -157.06M | -158.22M | -164.21M | -121.16M | -122.66M |
| Income Tax Expenses | 64.00K | -126.00K | -138.00K | -428.00K | -386.00K |
| Earnings from Continuing Operations | -157.13 | -158.10 | -164.08 | -120.74 | -122.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.13M | -158.10M | -164.08M | -120.74M | -122.27M |
| EBIT | -130.64M | -124.66M | -130.77M | -136.36M | -139.13M |
| EBITDA | -129.95M | -123.91M | -129.75M | -135.20M | -137.17M |
| EPS Basic | -6.70 | -8.42 | -10.22 | -7.93 | -8.71 |
| Normalized Basic EPS | -3.88 | -4.96 | -6.10 | -6.69 | -7.17 |
| EPS Diluted | -6.70 | -8.42 | -10.22 | -7.94 | -8.72 |
| Normalized Diluted EPS | -3.88 | -4.96 | -6.10 | -6.66 | -7.15 |
| Average Basic Shares Outstanding | 97.03M | 78.07M | 67.39M | 61.08M | 56.08M |
| Average Diluted Shares Outstanding | 97.03M | 78.07M | 67.39M | 61.34M | 56.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |